Dynamism of Ribosomal Protein RPL28 as Biomarker for Monitoring Epigenetic-initiated-breast-cancer Therapy

Sara Houngu¨¨¹, Blanche Aguida¹ and Callinice D. Capo-chichi^1,

¹Department of Biochemistry and Cell Biology, Division of Molecular Biology in Cancer and Nutrition (BMCN), Faculty of Sciences and Technics (FAST), University of Abomey Calavi (UAC), Abomey Calavi, BENIN

Cite this paper:
Sara Houngu¨¨, Blanche Aguida and Callinice D. Capo-chichi. Dynamism of Ribosomal Protein RPL28 as Biomarker for Monitoring Epigenetic-initiated-breast-cancer Therapy. American Journal of Biomedical Research. 2019; 7(1):21-26. doi: 10.12691/ajbr-7-1-5

Abstract

Background: Many oncology biomarkers were reported for breast cancer diagnosis and targeted therapy. Most biomarkers were hormonal receptors, but few studies integrated GATA transcription factors, nuclear envelop protein lamin A and ribosomal proteins, all of which were disrupted in cancer to facilitate cell proliferation, migration and metastasis. The overexpression of GATA6 in breast cancer cells is involved in epithelial-mesenchymal transition (EMT) while the overexpression of ribosomal large subunit (60S) protein RPL28 is involved in protein synthesis and cell proliferation. The objective of this study is to investigate in breast cancer cell line MCF7 the expression profile of GATA6 and RPL28 as biomarkers to evaluate the efficiency of breast cancer therapy with histone deacetylase inhibitor Suberoyl-Bis-Hydroxamic Acid (SBHA) in case that epigenetic modifications influence protein expression. Methods: Immuno-blot was used to assess GATA6 and RPL28 expression profile in MCF7 cell lysate before and after treatment with SBHA for 12h. GATA6 and RPL28 were also assessed in presence and absence of nuclear envelop protein lamin A in MCF7 stably transfected with exogenous wild type lamin A conjugated to red fluorescent protein (LA-RFP). Results: Our principal findings were that GATA6 and RPL28 were overexpressed in MCF7 lacking lamin A. GATA6 expression is higher in MCF7 control lacking lamin A. Exogenous transfection of LA-RFP in MCF7 was enough to reduce GATA6 and RPL28 at a background level like the one obtained with SBHA treatment. Conclusions: The significance of our study is that breast cancer therapy can be achieved with histone deacetylase inhibitor in case that epigenetic modifications underlie and initiate cancer mechanisms. The dynamism of biomarkers GATA6 and RPL28 can be used as bioindicators to evaluate anti-cancer drug effectiveness.

Keywords:
breast cancer epigenetic modifications GATA6 transcription factor ribosomal protein RPL28 Histone deacetylase inhibitor Suberoyl-Bis-Hydroxamic Acid lamin A

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Egue, M., Gnangnon, F.H.R, Akele-Akpo, M.T., Maxwell Parkin D. Cancer incidence in Cotonou (Benin), 2014-2016: First results from the cancer Registry of Cotonou. Cancer Epidemiol., 59: 46-50. Apr 2019.
[2]	Bahassi, E.M., Stambrook, P.J. Next-generation sequencing technologies: Breaking the sound barrier of human genetics. Mutagenesis. 29(5), 303-310. Sept 2014.
[3]	Cardoso, F., van't Veer, L.J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.Y., Brain, E., Causeret, S., DeLorenzi, M., et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med., 375(8), 717-729. Aug 25th 2016.
[4]	van der Merwe N, Peeters A.V., Pienaar, F.M., Bezuidenhout, J., van Rensburg, S.J., Kotze, M.J. Exome Sequencing in a Family with Luminal-Type Breast Cancer Underpinned by Variation in the Methylation Pathway. Int J Mol Sci., 18(2), 2-17. Feb 22. 2017.
[5]	Chang, C.S., Kitamura, E., Johnson, J., Bollag, R., Hawthorn, L. Genomic analysis of racial differences in triple negative breast cancer. Genomics, Oct 23 2018. pii: S0888-7543(18) 30045-4.
[6]	Nagini, S. Breast Cancer: Current Molecular Therapeutic Targets and New Players. Anticancer Agents Med Chem. 17(2). 152-163. 2017.
[7]	Capo-chichi, C.D., Gnangnon, F., Mekpossi, C., Houngue, S., Xu X.X., Olory-Togb¨¦, J.L. Presence of Lamin A is Required for GATA3 and ER¦Á Downregulation by Histone Deacetylase Inhibitor in Breast Cancer Cells. Journal of Cancer Research and Treatment, 6(3). 60-69. Oct 2018.
[8]	Capo-chichi, C.D., Cai, K.Q., Smedberg, J., Ganjei-Azar, P., Godwin, A.K., Xu X.X. Loss of A-type lamin expression compromises nuclear envelope integrity in breast cancer. Chin J Cancer, 30(6).415-425. Jun 2011.
[9]	Yu, C., Hong, H., Zhang, S., Zong, Y., Ma, J., Lu, A., Sun, J., Zheng, M. Identification of key genes and pathways involved in microsatellite instability in colorectal cancer. Mol Med Rep.,19(3).2065-2076. Mar 2019.
[10]	Song, Y., Tian, T., Fub, X., Wang, W., Li, S., Shi, T., Suo, A., Ruan, Z., Guo, H., Yao, Y. GATA6 is overexpressed in breast cancer and promotes breast cancer cell epithelial¨Cmesenchymal transition by upregulating slug expression. Experimental and Molecular Pathology, 2015; 99: 617-627.
[11]	Romagnolo, A.P.G., Romagnolo D.F., Selmi O.I. BRCA1 as Target for Breast Cancer Prevention and Therapy. Anti-Cancer Agents in Medicinal Chemistry, 15, 4-14. 2015.
[12]	Fregene, A. Newman, L.A. Breast Cancer in Sub-Saharan Africa: How Does It Relate to Breast Cancer in African-American Women? American Cancer Society, 2005. p1540.
[13]	Dolezal, J.M, Dash, A.P., Edward V. Prochownik, E.V. Diagnostic and prognostic implications of ribosomal protein transcript expression patterns in human cancers. BMC Cancer, 18: 275. 2018.
[14]	Hong, M., Kim, H., Kim, I. Ribosomal protein L19 overexpression activates the unfolded protein response and sensitizes MCF7 breast cancer cells to endoplasmic reticulum stress-induced cell death. Biochem Biophys Res Commun. 2014; 450: 673¨C8.